Precigen Shares Climb Following Positive PAPZIMEOS Launch Updates

Precigen shares are trading higher after H.C. Wainwright raised the price target to $9.00 from $8.50 post the Q3 report, citing a robust pipeline of patients from the successful PAPZIMEOS launch.